Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide has helped millions lose weight and improve metabolic health, but patients and providers must understand cardiovascular safety, including rare thrombotic events reported in some clinical trials. PlexusDx delivers compounded semaglutide from licensed 503A pharmacies with personalized dosing strategies and genetic screening to optimize your treatment safety and outcomes.
What the Research Shows About Semaglutide and Blood Clot Risk
GLP-1 receptor agonists like semaglutide were originally studied for type 2 diabetes and cardiovascular benefit. Large randomized trials, including the SUSTAIN and SELECT studies, tracked cardiovascular events across thousands of patients. While the majority of participants experienced weight loss and improved heart health markers, careful monitoring identified rare cases of deep vein thrombosis and pulmonary embolism—particularly in patients with existing cardiovascular disease or immobility risk factors.
The absolute incidence of clotting events remains low, and semaglutide's cardiovascular benefits often outweigh risks for appropriate candidates. However, certain populations—including those with prior blood clots, active malignancy, recent surgery, or prolonged immobility—require heightened vigilance and may benefit from alternative approaches or closer clinical oversight during treatment.
PlexusDx clinicians review your complete medical history, including thrombotic risk factors, before prescribing semaglutide injection or any GLP-1 medication. This personalized screening ensures you receive safe, evidence-based therapy aligned with your individual health profile.
Key Risk Factors for Blood Clots During GLP-1 Weight Loss Therapy
Certain conditions and lifestyle factors increase thrombotic risk and merit special consideration before starting semaglutide. These include personal or family history of deep vein thrombosis or pulmonary embolism, active cancer or recent cancer treatment, immobility from surgery or long-term bed rest, smoking, estrogen-containing birth control, and hereditary blood-clotting disorders like Factor V Leiden or prothrombin mutation.
Dehydration and rapid weight loss can transiently elevate clotting risk by concentrating blood proteins and reducing circulatory volume. Patients on semaglutide should maintain adequate hydration, stay physically active as tolerated, and report leg swelling, chest pain, shortness of breath, or other thrombotic warning signs immediately to their healthcare provider.
PlexusDx's intake questionnaire captures these risk factors comprehensively, allowing pharmacists and medical advisors to flag high-risk candidates and recommend safer alternatives or enhanced monitoring protocols.
Genetic Testing and Personalized Risk Assessment with PlexusDx
PlexusDx offers the Precision Peptide Genetic Test, a peptide-pathway genetic assessment that maps 14 signaling pathways and evaluates 49 peptides involved in appetite, weight regulation, and metabolism. While not a pharmacogenomic test, it reveals genetic variants in key appetite-control genes—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—that predict how your body responds to GLP-1 therapy.
These genetic insights help PlexusDx clinicians select the optimal medication (semaglutide, tirzepatide, or dual-compound formulas) and starting dose for your unique biology. Understanding your peptide-pathway genetics reduces trial-and-error dosing, minimizes side effects, and identifies patients who may benefit from alternative weight loss strategies if standard GLP-1 therapy carries elevated risk.
The Precision Peptide Genetic Test is available as a $99 add-on after your first month of treatment, giving PlexusDx the opportunity to establish baseline safety before offering deeper genetic personalization.
Safe Semaglutide Use and Monitoring Strategies for Weight Loss
If you and your PlexusDx clinician determine that semaglutide injection is right for you, several evidence-based practices minimize clotting risk. Start with the lowest effective dose—PlexusDx's compounded semaglutide begins at $149 per month, regardless of dose, so you can escalate safely without worrying about price barriers. Maintain consistent hydration (at least 8–10 glasses of water daily), engage in light-to-moderate activity like walking, and avoid prolonged sitting or immobility.
Attend all scheduled follow-up appointments so PlexusDx clinical advisors can monitor your weight loss progress, blood pressure, and any new symptoms. Report warning signs immediately: unilateral leg swelling or pain, chest discomfort, unexplained shortness of breath, or calf tenderness. If you undergo surgery or require prolonged bed rest during semaglutide therapy, contact your PlexusDx provider to discuss temporary dose adjustment or pausing treatment.
PlexusDx serves all 50 states without insurance requirements and accepts HSA/FSA funds, ensuring continuous access to your medication and clinical support—critical for uninterrupted, safe weight management.
Why Compounded Semaglutide from PlexusDx Offers Flexibility and Accessibility
PlexusDx sources semaglutide from licensed 503A compounding pharmacies, not mass-manufactured branded products. This allows customized dosing flexibility, faster dose adjustments, and lower costs—starting at just $149 per month for injection. Compounded medications meet rigorous quality and sterility standards while offering individualized formulation suited to your body's needs and response.
Unlike insurance-dependent brand-name GLP-1s that may face prior-authorization delays, PlexusDx compounded semaglutide is available immediately to all patients across the United States. No membership fees, no insurance requirements, and full HSA/FSA eligibility mean your weight loss therapy stays affordable and uninterrupted, even as your dose increases over time.
Your dose may need to go up—but your price won't. This PlexusDx commitment ensures you can pursue long-term, sustainable weight loss without financial anxiety derailing your health journey.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I use semaglutide if I have a family history of blood clots?
Family history of thrombosis warrants careful medical evaluation before starting semaglutide. PlexusDx clinicians will review your detailed history, assess your personal risk profile, and may recommend genetic testing or consultation with a cardiologist to determine if semaglutide is safe for you, or if an alternative GLP-1 compound or weight loss strategy is more appropriate.
What clinical evidence supports GLP-1 safety in weight loss therapy?
Large randomized trials like SELECT (2024) showed that semaglutide reduced cardiovascular events by 18% in overweight or obese adults, despite rare thrombotic cases. The cardiovascular benefits often outweigh clotting risks for most candidates, but individual assessment is essential.
How much does compounded semaglutide injection cost at PlexusDx?
PlexusDx compounded semaglutide injection starts at $149 per month and remains flat-priced across all three commitment tiers, regardless of dose escalation. All patients receive access without insurance, membership fees, or flat per-compound pricing increases.
What should I do if I notice leg swelling or chest pain while on semaglutide?
Stop semaglutide immediately and seek emergency care or contact your doctor right away if you develop unilateral leg swelling, calf pain, chest discomfort, or shortness of breath. These may signal deep vein thrombosis or pulmonary embolism and require urgent evaluation.
Can the Precision Peptide Genetic Test predict my clotting risk on semaglutide?
The Precision Peptide Genetic Test evaluates appetite and metabolism genes (GLP1R, GIPR, FTO, MC4R) to personalize your GLP-1 compound and dose, not pharmacogenomic or thrombotic markers. However, identifying your optimal medication reduces side effects and treatment errors, supporting overall safety. The test costs $99 and is available after your first month at PlexusDx.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Get Ozempic for Weight Loss Affordably
Mounjaro Pens: Are All Strengths and Designs the Same? Navigating Your Weight Loss Journey